321 related articles for article (PubMed ID: 29615436)
21. Cardiac [
Tingen HSA; Tubben A; Bijzet J; van den Berg MP; van der Meer P; Houwerzijl EJ; Muntinghe FLH; van der Zwaag PA; Glaudemans AWJM; Oerlemans MIFJ; Knackstedt C; Michels M; Hirsch A; Hazenberg BPC; Slart RHJA; Nienhuis HLA
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):681-690. PubMed ID: 37843599
[TBL] [Abstract][Full Text] [Related]
22. Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.
Ohiomoba RO; Youmans QR; Ezema A; Akanyirige P; Anderson AS; Bryant A; Jackson K; Mandieka E; Pham DT; Rich JD; Yancy CW; Okwuosa IS
Am Heart J; 2021 Jun; 236():13-21. PubMed ID: 33621542
[TBL] [Abstract][Full Text] [Related]
23. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
[TBL] [Abstract][Full Text] [Related]
24. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis.
Griffin JM; Chiu L; Axsom KM; Bijou R; Clerkin KJ; Colombo P; Cuomo MO; De Los Santos J; Fried JA; Goldsmith J; Habal M; Haythe J; Helmke S; Horn EM; Latif F; Hi Lee S; Lin EF; Naka Y; Raikhelkar J; Restaino S; Sayer GT; Takayama H; Takeda K; Teruya S; Topkara V; Tsai EJ; Uriel N; Yuzefpolskaya M; Farr MA; Maurer MS
Clin Transplant; 2020 Oct; 34(10):e14028. PubMed ID: 32623785
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
Müller ML; Butler J; Heidecker B
Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
[TBL] [Abstract][Full Text] [Related]
26. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
27. Hereditary transthyretin-related amyloidosis.
Finsterer J; Iglseder S; Wanschitz J; Topakian R; Löscher WN; Grisold W
Acta Neurol Scand; 2019 Feb; 139(2):92-105. PubMed ID: 30295933
[TBL] [Abstract][Full Text] [Related]
28. Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?
Ericzon BG; Wilczek HE; Larsson M; Wijayatunga P; Stangou A; Pena JR; Furtado E; Barroso E; Daniel J; Samuel D; Adam R; Karam V; Poterucha J; Lewis D; Ferraz-Neto BH; Cruz MW; Munar-Ques M; Fabregat J; Ikeda S; Ando Y; Heaton N; Otto G; Suhr O
Transplantation; 2015 Sep; 99(9):1847-54. PubMed ID: 26308415
[TBL] [Abstract][Full Text] [Related]
29. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
30. Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy.
Nelson LM; Penninga L; Villadsen GE; Mølgaard H; Eiskjaer H; Hillingsø JG; Rasmussen A
Clin Transplant; 2015 Dec; 29(12):1098-104. PubMed ID: 26361241
[TBL] [Abstract][Full Text] [Related]
31. Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid.
Hough A; Wearden J; de Almeida K; Kaiser S
Curr Cardiol Rep; 2020 Aug; 22(10):106. PubMed ID: 32770401
[TBL] [Abstract][Full Text] [Related]
32. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.
Gray Gilstrap L; Niehaus E; Malhotra R; Ton VK; Watts J; Seldin DC; Madsen JC; Semigran MJ
J Heart Lung Transplant; 2014 Feb; 33(2):149-56. PubMed ID: 24200511
[TBL] [Abstract][Full Text] [Related]
33. Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.
Piekarski E; Chequer R; Algalarrondo V; Eliahou L; Mahida B; Vigne J; Adams D; Slama MS; Le Guludec D; Rouzet F
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1108-1118. PubMed ID: 29511839
[TBL] [Abstract][Full Text] [Related]
34. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
[TBL] [Abstract][Full Text] [Related]
35. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
Kozlitina J; Garg S; Drazner MH; Matulevicius SA; Ayers C; Overton J; Reid J; Baras A; Rao K; Pandey A; Berry J; de Lemos JA; Grodin JL
J Card Fail; 2022 Mar; 28(3):403-414. PubMed ID: 34634447
[TBL] [Abstract][Full Text] [Related]
36. Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant.
Hikishima S; Sakai K; Akagi A; Yamaguchi H; Shibata S; Hayashi K; Nakano H; Kanemoto M; Usui Y; Taniguchi Y; Komatsu J; Nakamura-Shindo K; Nozaki I; Hamaguchi T; Ono K; Iwasa K; Yamada M
Intern Med; 2022 Aug; 61(15):2347-2351. PubMed ID: 35283385
[TBL] [Abstract][Full Text] [Related]
37. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.
Coniglio AC; Segar MW; Loungani RS; Savla JJ; Grodin JL; Fox ER; Garg S; de Lemos JA; Berry JD; Drazner MH; Shah S; Hall ME; Shah A; Khan SS; Mentz RJ; Pandey A
JACC Heart Fail; 2022 Feb; 10(2):129-138. PubMed ID: 35115086
[TBL] [Abstract][Full Text] [Related]
38. The use of diflunisal for transthyretin cardiac amyloidosis: a review.
Ibrahim M; Saint Croix GR; Lacy S; Fattouh M; Barillas-Lara MI; Behrooz L; Mechanic O
Heart Fail Rev; 2022 Mar; 27(2):517-524. PubMed ID: 34272629
[TBL] [Abstract][Full Text] [Related]
39. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
[TBL] [Abstract][Full Text] [Related]
40. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
